AbbVie (MEX:ABBV) Cash Flow for Dividends: MXN-216,256 Mil (TTM As of Mar. 2026)


MEX:ABBV AbbVie Inc MEX:ABBV
72 GF Score
Price MXN4,343.00
GF Value MXN3,624.05
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Cash Flow for Dividends?

AbbVie MEX:ABBV +2.31% 72 Cash Flow for Dividends is MXN-216,256 Mil as of Mar. 2026. GuruFocus rates MEX:ABBV with a GF Score™ of 72/100 and a GF Value™ of MXN3,624.05 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's cash flow for dividends for the three months ended in Mar. 2026 was MXN-55,649 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-216,256 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

AbbVie's quarterly payment of dividends declined from Sep. 2025 (MXN-53,400 Mil) to Dec. 2025 (MXN-52,415 Mil) but then increased from Dec. 2025 (MXN-52,415 Mil) to Mar. 2026 (MXN-55,649 Mil).

AbbVie's annual payment of dividends increased from Dec. 2023 (MXN-178,892 Mil) to Dec. 2024 (MXN-229,934 Mil) but then declined from Dec. 2024 (MXN-229,934 Mil) to Dec. 2025 (MXN-209,892 Mil).

AbbVie Cash Flow for Dividends Related Terms

AbbVie Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for AbbVie's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cash Flow for Dividends Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -189,980.15 -195,798.33 -178,891.60 -229,934.09 -209,892.45

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59,840.24 -54,792.97 -53,399.97 -52,414.59 -55,648.91
MEX:ABBV
72GF Score
AbbVie Inc MEX:ABBV
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-216,256 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of MXN-216,256 Mil mean?
AbbVie (MEX:ABBV) has a Cash Flow for Dividends of MXN-216,256 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for AbbVie and its competitors.
Is AbbVie's Cash Flow for Dividends too high?
AbbVie's current Cash Flow for Dividends is MXN-216,256 Mil. Overall, AbbVie has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Cash Flow for Dividends compare to MRK and JNJ?
AbbVie's Cash Flow for Dividends of MXN-216,256 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for AbbVie and its competitors. AbbVie's current Cash Flow for Dividends is MXN-216,256 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,624.05, compared to a current price of MXN4,343.00 — trading 19.8% above its estimated fair value. The current Cash Flow for Dividends is MXN-216,256 Mil. AbbVie's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Cash Flow for Dividends is MXN-216,256 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,343.00 is trading 19.8% above its estimated GF Value™ of MXN3,624.05. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Cash Flow for Dividends: MXN-216,256 Mil
  • GF Value™: MXN3,624.05 vs. price of MXN4,343.00 (19.8% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
72GF Score

Get the complete analysis for MEX:ABBV

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,343.00
Price
MXN3,624.05
GF Value